Lexaria Bioscience's DehydraTECH-Semaglutide Shows 48% Reduction In Overall Side Effects And 55% Reduction In Gastrointestinal Side Effects Compared To Rybelsus In Phase 1b Study; Says Recent Financings Support New 2026 Development Opportunities

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®

DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®

Recent financings create runway for prospective new 2026 development opportunities

KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4 DehydraTECH ® ( "DHT" ) study arms relative to the Rybelsus® control study arm.